Peter Handrinos is the Chair of the Boston Corporate Department. He practices corporate and securities law, with an emphasis on mergers and acquisitions, capital markets and venture capital transactions for life sciences and technology companies. Mr. Handrinos advises both public and private companies in connection with a broad range of matters, including:
- IPOs
- Follow-on offerings
- Strategic investments
- 144A offerings
- Cash and stock mergers
- Tender offers
- Going-private transactions
He counsels numerous start-up companies and venture capital firms in venture capital financings. Mr. Handrinos also regularly represents investment banks in connection with capital markets transactions. A significant portion of his practice involves general corporate work for ongoing clients on matters such as SEC compliance, securities and disclosure issues and corporate governance matters.
Mr. Handrinos was recognized in the 2012 and 2013 editions of Best Lawyers in America as a leader in mergers and acquisitions. He was also named as one of "New England's Best Lawyers" in 2013 by Best Lawyers in America and in the 2007 through 2012 editions of Chambers US: America’s Leading Lawyers for Business as a leader in Corporate/M&A.
Mr. Handrinos's recent transactions include representing:
- Barclays and BMO in US$75 million intial public offering by Tetraphase Pharmaceuticals
- Chiasma in US$595 million collaboration with Roche relating to Octreolin
- Radius Health in withdrawn US$61.8 million public offering
- Morgan Stanley and Jefferies in US$100 million follow-on offering by Immunogen
- American Superconductor in US$25 million convertible note and warrant financing
- MPM Capital and Kaiser Permanente Ventures in US$40.4 million Series C financing for Astute Medical
- MPM Capital and New Enterprise Associates in US$25 million Series B financing for Rhythm Pharmaceuticals
- J.P. Morgan, Cowen and Jefferies in US$258 million follow-on offering by ARIAD Pharmaceuticals
- J.P. Morgan in US$50.2 million follow-on offering by ZIOPHARM Oncology
- BIND Biosciences in US$47.25 million financing led by RUSNANO, Polaris Venture Partners, Flagship Ventures, ARCH Venture Partners and NanoDimension
- Selecta Biosciences in US$47.25 million financing led by RUSNANO, Polaris Venture Partners, Flagship Ventures, Orbimed and NanoDimension
- American Superconductor in its terminated US$265 million proposed acquisition of The Switch
- A123 Systems in US$254 million concurrent common stock and convertible subordinated notes offerings
- MPM Capital in several portfolio investments